Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Vildagliptin 50 mg Tablets Versus Galvus 50 mg Tablets in Healthy Thai Volunteers Under Fasting Conditions
TCTR20220923002Phase 1Not yet recruiting
- Sponsor
- Bio-innova
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vildagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Bio-innova. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
vildagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on TCTR20220923002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220923002.